Navigation Links
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
Date:11/2/2012

NEW YORK, Nov. 2, 2012 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Keryx Biopharmaceuticals, Inc. ("Keryx" or the "Company") (NasdaqCM: KERX).

(Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO )

The investigation focuses on whether the Company and its executives violated federal securities laws with respect to its disclosures concerning perifosine, an experimental drug that Keryx had been co-developing to treat those suffering from colorectal cancer.

On April 2, 2012, Keryx announced the top-line data from the Perifosine X-PECT Phase 3 Clinical Trial. The Company revealed that the trial for refractory advanced colorectal cancer did not meet the primary endpoint of improving overall patient survival versus capecitabine and a placebo.  On this disappointing news, Keryx share price plummeted from $4.98 on March 30, 2012 to $1.74 on April 2, 2012 – a decline of roughly 65 percent.

Request more information now by clicking here:  www.faruqilaw.com/KERX. There is no cost or obligation to you.

Take Action
If you purchased Keryx stock or options between June 1, 2009 and April 1, 2012 and would like to discuss your legal rights, visit www.faruqilaw.com/KERX.  You can also contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com or fmcconville@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding Keryx's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).  Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case.  All communications will be treated in a confidential manner.

FARUQI & FARUQI, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn:  Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Francis McConville, Esq.
fmcconville@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330


'/>"/>
SOURCE Faruqi & Faruqi, LLP
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Centers for Medicare & Medicaid Services Win 2012 National Cybersecurity Innovation Award
2. Law Office of Brodsky & Smith, LLC Announces Investigation of Complete Genomics, Inc.
3. Hawaii Tech Asia Takes Hawaii & US Entrepreneurs To China
4. Frost & Sullivan Recognizes A*STAR, Singapore with the 2012 Asia Pacific National Innovation Development Award
5. Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference
6. AtheroNova to Present at Rodman & Renshaw 14th Annual Healthcare Conference in New York City
7. First Evidence that Adipose Stem Cell-Based Critical Limb Ischemia Treatment is Safe & Effective is published in Circulation Journal by Lead Investigator Dr. Han Cheol Lee of Pusan National University
8. Marken Opens Two Pharmaceutical Depots In New York & Germany
9. The Leukemia & Lymphoma Society Awards $12 Million in Research Grants in Four Critical Areas of Unmet Medical Need
10. All Market Research New Report @ The Worldwide Industry & Regional Market Opportunities With Forecasts to 2016 for Amplifiers and Integrated Microwave Assemblies. (Code name: AIMAs)
11. Spectrometry Market (Atomic, Molecular and Mass Spectrometry) - Global Scenario, Trends, Industry Analysis, Size, Share & Forecast 2011 - 2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... ... From industry leaders, sports stars, and Hollywood icons to thousands of everyday, ... had lost all hope. Their stories are told here. , Chapter 13: ... “Neil takes readers on a riveting journey through the past, present and future of ...
(Date:9/20/2017)... ... September 20, 2017 , ... RoviSys, a leading ... today the opening of an office in Taipei, Taiwan. This new location allows ... while developing new relationships in the region. Located in the Neihu area of ...
(Date:9/19/2017)... ... September 19, 2017 , ... Participants of this educational ... fume hood. Along with the advantages and disadvantages of ductless, filtered fume hoods, ... in the laboratory. , Attendees will learn from an industry expert about the ...
(Date:9/19/2017)... ... 2017 , ... VetStem Biopharma ’s CEO and founder, Dr. Bob Harman DVM, MPVM, is ... "Stem Cell Therapy: A Rising Tide". Dr. Harman and Dr. Riordan met in 2003 ... interest in the potential of stem cell therapy and a fast friendship was formed. , ...
Breaking Biology Technology:
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University ... adopting ground breaking 3D fingerprint minutiae recovery and matching technology, pushing ... for use in identification, crime investigation, immigration control, security of access ... ... A research team led by Dr Ajay ...
Breaking Biology News(10 mins):